Berciano-Guerrero, MA – 2022
Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine-refractory differentiated thyroid cancer
by prodriguez | Jan 1, 2022 | Publicaciones - CIMO-02 | 0 comments